TD Cowen Out Negative on Moderna (MRNA): 'mRNA-1345 (RSV) Appears Less Durable Than GSK Beyond 6 Months'
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a Market Perform rating and $75.00 price target on Moderna (NASDAQ: MRNA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
